MedPath

A study to compare effectiveness amongst two drugs ,one is injection desferoxamine with tablet deferasirox as a chelator in thalassemia patients

Phase 4
Conditions
Health Condition 1: null- THALASEMIA PATIENTS OF AGE GROUP 3 YEAR TO 18 YEARS
Registration Number
CTRI/2017/08/009441
Lead Sponsor
Dr Ratna D Bhojak
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Thalassemia major Patients

2 Pediatric age group 3 years to 18 years 3 On regular Deferasirox Therapy

4 Serum ferritin more than 1000mg/dl

5 With positive consent for study

Exclusion Criteria

1 Pt <3years

2 Pt > 18years

3 Patient with negative consent

4 Renal failure

5 Cataract

6 Ototoxicity

HIV positive

Hepatitis B positive

Av block

Asthma

On going infection( temporary exclusion included on recovery)

Severe allergy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To measure consecutive serum ferritin level in Participant with β Thalassemia major every 2 month with ongoing dosage of iron chelators ,admitted in Paediatric ward sir T hospital BhavnagarTimepoint: 6 months
Secondary Outcome Measures
NameTimeMethod
THE VELOCITY IN DECREASING SERUM FERRITIN IN INJECTION CHELATOR IS BETTER THAN ORAL FORMTimepoint: 6 MONTHS
© Copyright 2025. All Rights Reserved by MedPath